Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced its five-year growth ...

Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.

Congressional Republicans probably won’t take another stab at repealing Obamacare during Donald Trump's second administration ...

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...

The Washington Examiner prides itself on its in-depth, enterprise, and investigative reporting. Here is a summary of our weekly series in 2024.

AI can compare thousands of images to uncover dangerous patterns, create ultra-high resolution scans from low-res images and ...

Recalls can be issued for a variety of reasons, from undeclared allergens to plastic and bacterial contamination.

Qiagen has received clearance from U.S. regulators to market its gastrointestinal-illness test.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

The product may be used to treat a condition that the American Academy of Ophthalmology says affects around 20 million ...

Despite millions of cases of norovirus in the U.S. each year—and a current surge in outbreaks—there is still no vaccine for ...